Uncategorized
This week in Drug Discovery (3-7 August 2026)
News round-up for 3-7 August by Diana Turner, Content Team at DDW.
This week’s news round-up highlights new clinical trial results that demonstrate positive outcomes in Parkinson’s, colorectal cancer and Bundibugyo ebolavirus, as well as the first ever trial of a fridge-free vaccine. Elsewhere, Ractigen Therapeutics closed a new financing round exceeding $31 million.
The top stories:
Trial shows significant improvements in early Parkinson’s disease
BioVie has announced results from its Phase II SUNRISE-PD trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease (PD).
Targeted therapy shows promise in advanced colorectal cancer
A targeted antibody therapy combined with standard chemotherapy has shown early signs of tumour shrinkage and disease control in patients with advanced bowel cancer.
Phase I trial “a major step forward” against Ebola outbreak
Following Health Canada’s authorisation, the first participants have been vaccinated in Moderna’s Phase I clinical study evaluating mRNA-1469, an mRNA vaccine to prevent Bundibugyo ebolavirus (BDBV).
Fridge-free vaccine effective at 30°C for at least two years
The world-first trial of a fridge-free tetanus-diphtheria vaccine has produced encouraging results that could improve access worldwide to crucial treatments.
Ractigen Therapeutics closes over $31 million financing
Ractigen Therapeutics, a clinical-stage biotechnology company pioneering small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery systems, has closed a new financing round exceeding $31 million (over RMB 200 million).
The post This week in Drug Discovery (3-7 August 2026) appeared first on Drug Discovery World (DDW).